← All trials
NCT06517823
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Apr 26, 2024
- Primary completion
- Oct 4, 2024
- Completion date
- Oct 11, 2024
- First posted
- Jul 24, 2024
- Last posted
- Nov 27, 2024
- Enrollment
- 190
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Laboratorios Silanes S.A. de C.V.Lead sponsor
- Clinical Research Institute S.C.Official
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.